Literature DB >> 23341332

Nonreciprocal chromosomal translocations in renal cancer involve multiple DSBs and NHEJ associated with breakpoint inversion but not necessarily with transcription.

Hanif Ali1, Angelika Daser, Paul Dear, Henry Wood, Pamela Rabbitts, Terence Rabbitts.   

Abstract

Chromosomal translocations and other abnormalities are central to the initiation of cancer in all cell types. Understanding the mechanism is therefore important to evaluate the evolution of cancer from the cancer initiating events to overt disease. Recent work has concentrated on model systems to develop an understanding of the molecular mechanisms of translocations but naturally occurring events are more ideal case studies since biological selection is absent from model systems. In solid tumours, nonreciprocal translocations are most commonly found, and accordingly we have investigated the recurrent nonreciprocal t(3;5) chromosomal translocations in renal carcinoma to better understand the mechanism of these naturally occurring translocations in cancer. Unexpectedly, the junctions of these translocations can be associated with site-specific, intrachromosomal inversion involving at least two double strand breaks (DSB) in cis and rejoining by nonhomologous end joining or micro-homology end joining. However, these translocations are not necessarily associated with transcribed regions questioning accessibility per se in controlling these events. In addition, intrachromosomal deletions also occur. We conclude these naturally occurring, nonreciprocal t(3;5) chromosomal translocations occur after complex and multiple unresolved intrachromosomal DSBs leading to aberrant joining with concurrent interstitial inversion and that clonal selection of cells is the critical element in cancer development emerging from a plethora of DSBs that may not always be pathogenic.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23341332     DOI: 10.1002/gcc.22038

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  5 in total

1.  Transflip mutations produce deletions in pancreatic cancer.

Authors:  Alexis L Norris; Hirohiko Kamiyama; Alvin Makohon-Moore; Aparna Pallavajjala; Laura A Morsberger; Kurt Lee; Denise Batista; Christine A Iacobuzio-Donahue; Ming-Tseh Lin; Alison P Klein; Ralph H Hruban; Sarah J Wheelan; James R Eshleman
Journal:  Genes Chromosomes Cancer       Date:  2015-05-29       Impact factor: 5.006

Review 2.  A role for epigenetics in the formation of chromosome translocations in acute leukemia.

Authors:  Heidi J Gill Super
Journal:  Cancer Genet       Date:  2015-03-18

Review 3.  Dynamics of double strand breaks and chromosomal translocations.

Authors:  Olga V Iarovaia; Mikhail Rubtsov; Elena Ioudinkova; Tatiana Tsfasman; Sergey V Razin; Yegor S Vassetzky
Journal:  Mol Cancer       Date:  2014-11-18       Impact factor: 27.401

Review 4.  The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer.

Authors:  Brock J Sishc; Anthony J Davis
Journal:  Cancers (Basel)       Date:  2017-07-06       Impact factor: 6.639

5.  Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.

Authors:  Thomas J Mitchell; Samra Turajlic; Andrew Rowan; David Nicol; James H R Farmery; Tim O'Brien; Inigo Martincorena; Patrick Tarpey; Nicos Angelopoulos; Lucy R Yates; Adam P Butler; Keiran Raine; Grant D Stewart; Ben Challacombe; Archana Fernando; Jose I Lopez; Steve Hazell; Ashish Chandra; Simon Chowdhury; Sarah Rudman; Aspasia Soultati; Gordon Stamp; Nicos Fotiadis; Lisa Pickering; Lewis Au; Lavinia Spain; Joanna Lynch; Mark Stares; Jon Teague; Francesco Maura; David C Wedge; Stuart Horswell; Tim Chambers; Kevin Litchfield; Hang Xu; Aengus Stewart; Reza Elaidi; Stéphane Oudard; Nicholas McGranahan; Istvan Csabai; Martin Gore; P Andrew Futreal; James Larkin; Andy G Lynch; Zoltan Szallasi; Charles Swanton; Peter J Campbell
Journal:  Cell       Date:  2018-04-12       Impact factor: 41.582

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.